NCT07100925 2025-08-03A Study of Tolododekin Alfa (ANK-101) in Renal Allograft Recipients With High Risk Cutaneous Squamous Cell CarcinomaAnkyra Therapeutics, IncPhase 1 Not yet recruiting20 enrolled